wildpixel Fresh from its large, $380mn IPO in January, CG Oncology (NASDAQ:CGON) achieved high success after its bladder cancer molecule cretostimogene grenadenorepvec demonstrated a 75.2% complete response at any time in 105 patients. The study was a phase 3 monotherapy study in NMIBC or high-risk non-muscle invasive bladder cancer that's unresponsive to Bacillus Calmette Guerin. This data, presented on May 3, was quickly followed on May 24 by data from a phase 2 study of the same molecule, this time in co ...

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monothe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ | --- | --- | |--------------------------------------- ...

Financial Results Announcement - CG Oncology, Inc. announced its financial results for the quarter ended June 30, 2024 [6] - The press release detailing the financial results was issued on August 8, 2024 [6] - The press release is attached as Exhibit 99.1 and incorporated by reference [6] Regulatory and Compliance Information - The information in the Form 8-K, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act [7] - The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [5] - The report was signed by Josh Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc. [10] Company Classification and Market Information - CG Oncology, Inc. is classified as an emerging growth company [6] - CG Oncology, Inc. is registered on the Nasdaq Global Select Market under the trading symbol CGON [4] Company Contact Information - The company's principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California 92618 [2] - The company's telephone number is (949) 409-3700 [5]

th 11 elect E i = ad pl 101 Com 01 11 -1 F Ti A LEAST Property TE p nt 1 lar ----------- i P in The Property action t r H 2017 th n 1000 Phone 34 and live y ckly E in wildpixel Maybe different isn't always better, but it can be just as good. CG Oncology (NASDAQ:CGON) is different from the biotechs I normally prefer to look at, as the company doesn't really have a platform or a pipeline beyond its lead candidate cretostimogene grenadenorepvec, an oncolytic adenovirus targeted at non-muscle invasive bladder c ...

Date of report (Date of earliest event reported) May 9, 2024 CG Oncology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact Name of Registrant as Specified in Charter) Delaware 001-41925 37-1611499 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618 (949) 409-3700 (Address an ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-41925 CG Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________________ TO _____________________ Commission File Number 001-41925 CG Oncology, Inc. (Exact name of registrant as specified in its Charter) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (State or ...